Organon & Co (OGN) support and resistance · P/E 3.4, rev $6.40B
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
This page maps Organon & Co (OGN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new OGN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the OGN quote page for the session range and the stock page for the full model.
Not investment advice.